Analyst Rating Update on Zoetis (ZTS)

Zoetis (ZTS) : Zacks Investment Research ranks Zoetis (ZTS) as 1, which is a Strong Buy recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 1.8, which indicates as a Buy.

Zoetis (ZTS) stock is expected to deviate a maximum of $5.72 from the average target price of $53.13 for the short term period. 8 Street Experts have initiated coverage on the stock with the most promising target being $62 and the most muted being $45.

For the current week, the company shares have a recommendation consensus of Buy. Also, Jefferies maintains its rating on Zoetis (NYSE:ZTS). The global brokerage major raises the current price target from $57 per share to $58 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on June 14, 2016.


Zoetis (NYSE:ZTS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $52.15 and $50.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $52.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $51.21, notching a gain of 3.00% for the day. The total traded volume was 5,425,272 . The stock had closed at $49.72 on the previous day.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.